IndustryCompany release

OmniAb raises 2026 revenue and cash guidance as Lilly ion channel deal adds up to $370M

🇺🇸 OmniAb, Inc. (OABI) · Fri 30 Oct 2026

The antibody discovery company reported third-quarter revenue of $4.0M and a $15.7M net loss, while lifting full-year revenue and year-end cash forecasts.

OmniAb (NASDAQ: OABI) published its third-quarter 2026 results on 30 October 2026, reporting revenue of $4.0M and a net loss of $15.7M for the period.

The company raised its full-year 2026 revenue guidance to a range of $35M to $39M. It also lifted its year-end cash guidance to between $53M and $57M.

OmniAb also disclosed a new ion channel licence agreement with Eli Lilly. The deal carries potential milestone payments of up to $370M. The summary available does not give upfront payment terms, royalty arrangements or the targets involved.

Separately, the company said that in October it widened sales of its xPloration platform to all customers. No further detail on the platform's pricing or uptake was provided.

What it means for your team

  • Milestone-based licensing deals such as the Lilly agreement pay out only if development and regulatory stages are met, so the $370M figure is a ceiling, not committed revenue.
  • Teams working with partnered antibody programmes should note that ion channel targets are an expanding area of collaboration between discovery platforms and large pharma.
  • Wider commercial access to xPloration may broaden the range of sponsors using OmniAb technology, which is relevant to partner and supplier due-diligence.

Company's press release (SEC filing): OmniAb, Inc. ↗

Article written by VigiEye from the official source (OmniAb, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →